October 29th 2024
Data from TROPiCS-04 did not meet the primary end point of overall survival among those with locally advanced or metastatic urothelial cancer.
October 16th 2024
The decision is backed by robust efficacy data from the phase 3 ENVISION trial, evaluating UGN-102 in patients with non-muscle invasive bladder cancer.
October 9th 2024
TAR-200 plus cetrelimab did not yield significant results vs chemoradiation in muscle-invasive bladder cancer.
September 24th 2024
Phase 3 EV-302 results supported the approval, showing a statically significant survival benefit compared with chemotherapy in urothelial carcinoma.
September 17th 2024
Data from the SunRISe-4 trial demonstrate the benefit of adding TAR-200 to checkpoint inhibition among patients with muscle-invasive bladder cancer.
Atezolizumab May Yield OS Benefit in PD-L1+ Advanced Urothelial Carcinoma
Treatment with atezolizumab monotherapy yields an acceptable toxicity profile compared with chemotherapy among those with advanced or metastatic urothelial carcinoma.
Enfortumab Vedotin Combo Is Approved by FDA for Advanced Urothelial Cancer
Patients with locally advanced or metastatic urothelial cancer may now receive enfortumab vedotin plus pembrolizumab following its approval by the FDA.
Frontline Nivolumab/Chemo Earns FDA Priority Review in Urothelial Carcinoma
The FDA has set a Prescription Drug User Fee Act date of April 5, 2024 for nivolumab plus chemotherapy in unresectable or metastatic urothelial carcinoma.
UGN-102 Yields Complete Responses in Non-Muscle Invasive Bladder Cancer
If approved, UGN-102 may become the first non-surgical option for patients with low-grade intermediate-risk non–muscle invasive bladder cancer, says Sandip Prasad, MD.
Nadofaragene Firadenovec Produces Enduring Clinical Activity in NMIBC
Data from the phase 3 CS-003 study underscore the importance of long-term follow-up findings with novel therapies for high-grade non–muscle-invasive bladder cancer, says Stephen A. Boorjian MD.
Chemo/Nephroureterectomy Increases pCR Likelihood in Urothelial Carcinoma
Patients receiving neoadjuvant chemotherapy plus radical nephroureterectomy for upper tract urothelial carcinoma appear more likely to experience nodal downstaging.
Cretostimogene Grenadenorepvec Yields Durable Responses in NMIBC
More than half of the patients with non–muscle-invasive bladder cancer in the BOND-003 trial achieve a complete response at 6 months following treatment with cretostimogene grenadenorepvec.
Enfortumab Vedotin Shows Meaningful, Sustained OS Benefit in Bladder Cancer
Data from the phase 3 EV-301 study turn up no new safety signals in patients with advanced urothelial carcinoma treated with enfortumab vedotin.
Durvalumab Combo Offers OS/EFS Benefit in Muscle-Invasive Urothelial Carcinoma
More than half of resected patients with muscle-invasive urothelial carcinoma achieve a pathologic response with durvalumab plus neoadjuvant cisplatin/gemcitabine in the phase 2 SAKK 06/17 trial.
FDA Accepts Resubmitted BLA for N-803 Plus BCG in NMIBC
The regulatory agency has set a Prescription Drug User Fee Act date of April 23, 2024 for N-803 plus BCG as a treatment for BCG-unresponsive, non–muscle invasive bladder carcinoma.
TAR-200 Yields Complete Responses in BCG-Unresponsive High-Risk NMIBC
Efficacy and safety data from the phase 2b SUNRISE-1 trial support the ongoing evaluations of TAR-200 as a treatment for patients with BCG-unresponsive high-risk non–muscle-invasive bladder cancer.
Enfortumab Vedotin Combo Boosts Survival Vs Chemo in Urothelial Carcinoma
Data from the phase 3 EV-302 trial support enfortumab vedotin plus pembrolizumab as a potential standard of care in locally advanced or metastatic urothelial carcinoma.
Nivolumab/Chemo Yields Survival Benefits in Metastatic Urothelial Carcinoma
Treatment with nivolumab plus gemcitabine-cisplatin appears to confer rapid and enduring responses in patients with unresectable or metastatic urothelial carcinoma in the phase 3 CheckMate 901 trial.
Don’t Be Afraid to Ask Questions Along the Bladder Cancer Journey, Patients and Clinicians Advise
A patient with bladder cancer recounts his diagnosis while Rohit Jain, MD, and Anand B. Shah, PharmD, BCOP, review treatment options and the toxicity associated with them.
Pembrolizumab Yields Meaningful DFS in Muscle-Invasive Urothelial Carcinoma
Investigators will continue to assess overall survival in patients treated with pembrolizumab for localized muscle-invasive urothelial carcinoma as part of the phase 3 AMBASSADOR trial.
Pembrolizumab Combo Improves PFS/OS Vs Chemo in Urothelial Carcinoma
Combining pembrolizumab with enfortumab vedotin-ejfv significantly improves responses vs chemotherapy among patients with previously untreated locally advanced or metastatic urothelial carcinoma.
EMA Accepts Application for Erdafitinib in EGFR+ Urothelial Carcinoma
Findings from the phase 3 THOR study support the marketing authorization application for erdafitinib as a treatment for those with advanced or metastatic urothelial cancer harboring FGFR3 alterations.
Radiation and Radical Cystectomy Yield Similar OS in Node+ Bladder Cancer
Real-world data suggest that the presence of pelvic lymphadenopathy should not be viewed as a contraindication to trimodality therapy in nonmetastatic clinically node-positive bladder cancer.
FDA Accepts sNDA for Erdafitinib in FGFR+ Advanced Urothelial Carcinoma
Data from the phase 3 THOR study support the supplemental biologics license application for erdafitinib in previously treated advanced or metastatic urothelial carcinoma with FGFR3 alterations.
Frontline Treatments and Cisplatin Eligibility in Metastatic Bladder Cancer
Dr Jain discusses frontline treatment options, cisplatin eligibility criteria, and therapy considerations for metastatic bladder cancer.
An Unusual Case of Urothelial Carcinoma
During Morning Rounds, Petros Grivas, MD, and his treating team debate the diagnosis of a patient with urothelial carcinoma as it has an unusual presentation.
Advanced Bladder Cancer: Informing Selection of 2L Therapy
Leaders in bladder cancer management consider factors that aid in their selection of second-line therapy.
Improving Care in Bladder Cancer: Palliative Radiation and Treatment Breaks
In light of individual patient needs, perspectives are shared on the roles of palliative radiation and treatment breaks in the setting of advanced bladder cancer.
Patient Experience and Collaborative Care in Metastatic Bladder Cancer
Shared patient perspectives and conversation centered around collaboration in clinical care for metastatic bladder cancer, including the oncology pharmacists’ role in treatment decisions.
Overview of Metastatic Bladder Cancer
Rohit Jain, MD, MPH provides an overview of metastatic bladder cancer, discussing differences in urothelial carcinoma based on location, patient presentations, diagnosis, and staging.
Legislation Needed to Overcome Chemo Shortage; Expert Discusses Impact in GU
Amid the recent cisplatin shortages across the United States, a pharmacy expert discusses how the treatment of bladder cancer has been affected, especially in the muscle-invasive subtype.
Followup With Patients on Maintenance Therapy for Bladder Cancer
A brief discussion on optimal follow-up practices with patients on therapy for advanced bladder cancer.
Bladder Cancer: Treatment Options for Patients With a Partial Response
Following a patient with bladder cancer who had a partial response to frontline therapy, panelists consider the branching treatment pathway.
UGN-102 May be an Effective Non-Surgical Option For Bladder Cancer Subtype
Among patients with low-grade, non–muscle invasive bladder cancer, intravesical UGN-102 appears to improve outcomes vs standard surgical treatment in two phase 3 trials.
Data Support Trimodality Therapy in Suitable Candidates With MIBC
Investigators of a meta-analysis report no significant difference in outcomes when comparing trimodality therapy and radical cystectomy for the treatment of muscle-invasive bladder cancer.